![]() |
|
|
Vol. 303, Issue 3, 1238-1247, December 2002
Institut National de la Santé et de la Recherche
Médicale, Toulouse, France (N.M., V.V., D.C., P.V., C.C);
Departament de Bioquimica i Biologia Molecular, Facultat de Biologia,
Universitat de Barcelona, Barcelona, Spain (L.M., A.Z., X.T.); and
Solvay Pharmaceuticals, CCS, Hannover, Germany (Y.F.)
Tyramine and benzylamine have been described as stimulators of glucose
transport in adipocytes. This effect is dependent on amine oxidation by
monoamine oxidase (MAO) or semicarbazide-sensitive amine oxidase (SSAO)
and on the subsequent hydrogen peroxide formation as already
demonstrated by blockade with oxidase inhibitors or antioxidants and
potentiation with vanadate. In this work, we extended these
observations to skeletal muscle and cardiac myocytes using in vitro and
in vivo approaches. Tissue distribution studies showed that substantial
extrahepatic peripheral MAO activities exist in kidney and gut, but
also in insulin-sensitive tissues: heart, adipose tissue, and skeletal
muscles. SSAO activity is also widely distributed and present at a
lower level than MAO, except in fat depots where both oxidases were
equally involved in tyramine oxidation. When tested in vitro at
millimolar doses, tyramine caused a large stimulation of glucose
transport in rat adipocytes and in skeletal and cardiac muscles. In
vivo administration of tyramine (4 mg/kg i.p.) lowered the
hyperglycemic responses to a glucose challenge in control and in
streptozotocin-treated rats. This positive effect on glucose disposal
was obtained without vanadate and was abolished by SSAO and MAO
inhibitors. Tyramine increased hexose uptake in vivo in
insulin-sensitive tissues, whereas it induced only transient effects on
plasma insulin or cardiovascular parameters. In conclusion, activation
of the amine oxidases present in insulin-sensitive tissues induces
insulin-like effects, readily detectable in vitro, and increasing
peripheral glucose utilization in vivo.
This article has been cited by other articles:
![]() |
L. K. Gilliam, J. P. Palmer, and G. J. Taborsky Jr. Tyramine-Mediated Activation of Sympathetic Nerves Inhibits Insulin Secretion in Humans J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 4035 - 4038. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Salmi and S. Jalkanen Developmental regulation of the adhesive and enzymatic activity of vascular adhesion protein-1 (VAP-1) in humans Blood, September 1, 2006; 108(5): 1555 - 1561. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Iglesias-Osma, M. J. Garcia-Barrado, V. Visentin, M. F. Pastor-Mansilla, S. Bour, D. Prevot, P. Valet, J. Moratinos, and C. Carpene Benzylamine Exhibits Insulin-Like Effects on Glucose Disposal, Glucose Transport, and Fat Cell Lipolysis in Rabbits and Diabetic Mice J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1020 - 1028. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Abella, L. Marti, M. Camps, M. Claret, J. Fernandez-Alvarez, R. Gomis, A. Guma, N. Viguerie, C. Carpene, M. Palacin, et al. Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 Activity Exerts an Antidiabetic Action in Goto-Kakizaki Rats Diabetes, April 1, 2003; 52(4): 1004 - 1013. [Abstract] [Full Text] [PDF] |
||||